enGene (NASDAQ:ENGN) Issues Quarterly Earnings Results, Misses Estimates By $0.18 EPS

enGene (NASDAQ:ENGN) announced its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18), Zacks reports.

enGene Stock Performance

Shares of NASDAQ ENGN traded up $0.08 during midday trading on Monday, hitting $8.77. 84,617 shares of the stock traded hands, compared to its average volume of 404,904. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.34 and a current ratio of 10.34. enGene has a one year low of $2.65 and a one year high of $11.14. The firm has a market capitalization of $566.35 million, a P/E ratio of -4.62 and a beta of -0.28. The firm has a 50-day moving average of $7.89 and a two-hundred day moving average of $5.76.

Institutional Investors Weigh In On enGene

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC raised its stake in enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after buying an additional 35,327 shares during the last quarter. Millennium Management LLC raised its holdings in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares during the period. Paloma Partners Management Co purchased a new stake in enGene in the 2nd quarter worth approximately $38,000. Finally, Cresset Asset Management LLC acquired a new stake in enGene during the second quarter valued at $36,000. 64.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on ENGN shares. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a research report on Tuesday, October 14th. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research report on Wednesday, November 12th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd. Citizens Jmp boosted their target price on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Wednesday, November 12th. Finally, UBS Group increased their price target on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, enGene has a consensus rating of “Moderate Buy” and a consensus target price of $22.38.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.